Ranolazine in patients with chronic coronary syndromes: real-world data provide new evidence on the antiarrhythmic properties of the drug
Our study, performed in a subset of the Italian CCS population, showed that Ran therapy was safe and associated with a long-term reduced AF incidence.
Authors
- Stefania Mazzoni
- Luca Degli Esposti (ORCID: https://orcid.org/0000-0002-7020-6659)
- Emanuele Santamaria
- Melania Dovizio
- C Cagnoni
- Niccolò Marchionni (ORCID: https://orcid.org/0000-0002-8101-4695)
- Elisabetta Cerbai (ORCID: https://orcid.org/0000-0001-7839-1361)
- Stefano Fumagalli (ORCID: https://orcid.org/0000-0002-6950-3875)
- Carlo Fumagalli (ORCID: https://orcid.org/0000-0001-7963-5049)
- Giulia Spanalatte
- Arianna Tariello
Institutions
- University of Campania "Luigi Vanvitelli" (IT)
- University of Chieti-Pescara (IT)
- Intensive Care Society (GB)
- Azienda Ospedaliero-Universitaria Careggi (IT)
- University of Campania "Luigi Vanvitelli" (IT)
- Innovative Technologies Center (Greece) (GR)
- Health Economics and Outcomes Research (United Kingdom) (GB)
- Steris (United States) (US)
- Institute of Pharmacology (CZ)
- University of Florence (IT)
Publication Details
- Journal
- European Heart Journal - Cardiovascular Pharmacotherapy
- Published
- 2025-09-30
- DOI
- https://doi.org/10.1093/ehjcvp/pvaf074
- Primary Topic
- Cardiac electrophysiology and arrhythmias
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Menarini Group